Trial Profile
A Randomized, Open-label, Parallel, Phase I/II Single-Dose Administration Trial of TLC599 in Subjects With Osteoarthritis of the Knee
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 09 May 2022
Price :
$35
*
At a glance
- Drugs Dexamethasone (Primary)
- Indications Osteoarthritis
- Focus Adverse reactions
- Sponsors Taiwan Liposome Company
- 03 Sep 2018 According to a Taiwan Liposome Company media release, data from this study will be presented at the 20th Asia Pacific League of Associations for Rheumatology Congress (APLAR) on Sep 2018.
- 20 Aug 2018 Results presented in a Taiwan Liposome Company media release.
- 03 Jan 2017 According to a Taiwan Liposome Company media release, the observation period has lengthened to 24 weeks compared to the 12 week duration in this trial to determine the maximum duration of efficacy.